Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dermatomyositis - Pipeline Review, H2 2016, provides an overview of the Dermatomyositis (Musculoskeletal Disorders) pipeline landscape.
Dermatomyositis is a rare inflammatory disease which is characterized by chronic muscle inflammation accompanied by muscle weakness. Symptoms of dermatomyositis include a distinctive skin rash, muscle weakness, and inflammatory myopathy, or inflamed muscles. Risk factors include age and gender. Treatment includes corticosteroids.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dermatomyositis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Dermatomyositis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Dermatomyositis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Dermatomyositis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 4, 1 and 2 respectively.Dermatomyositis.
Dermatomyositis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Dermatomyositis (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Dermatomyositis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Dermatomyositis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Dermatomyositis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Dermatomyositis (Musculoskeletal Disorders)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Dermatomyositis (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Dermatomyositis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
F. Hoffmann-La Roche Ltd
Hope Pharmaceuticals Inc
Idera Pharmaceuticals Inc
MedImmune LLC
Neovacs SA
Novartis AG
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Dermatomyositis Overview 6
Therapeutics Development 7
Pipeline Products for Dermatomyositis - Overview 7
Dermatomyositis - Therapeutics under Development by Companies 8
Dermatomyositis - Pipeline Products Glance 9
Clinical Stage Products 9
Early Stage Products 10
Dermatomyositis - Products under Development by Companies 11
Dermatomyositis - Companies Involved in Therapeutics Development 12
F. Hoffmann-La Roche Ltd 12
Hope Pharmaceuticals Inc 13
Idera Pharmaceuticals Inc 14
MedImmune LLC 15
Neovacs SA 16
Novartis AG 17
Dermatomyositis - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
IMO-8400 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
JBT-101 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
MEDI-7734 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
siponimod - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
sodium thiosulfate - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
tocilizumab - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Vaccine to Target IFN-Alpha for Chronic Viral Infections, Dermatomyositis and Systemic Lupus Erythematosus - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
Dermatomyositis - Dormant Projects 56
Dermatomyositis - Product Development Milestones 57
Featured News & Press Releases 57
Sep 28, 2016: Corbus Announces Data on Effects of Resunab (JBT-101) in a Clinical Research Model of Resolution of Inflammation 57
Nov 09, 2015: Idera Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of IMO-8400 in Patients with Dermatomyositis 58
Oct 13, 2015: Corbus Pharmaceuticals to Present at the 14th Annual BIO Investor Forum 59
Aug 06, 2015: Corbus Pharmaceuticals to Present at the Canaccord Genuity Growth Conference on August 13, 2015 59
Jul 13, 2015: Corbus Pharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of Resunab for the Treatment of Dermatomyositis 59
Jun 16, 2015: Neovacs initiates clinical program in Dermatomyositis 60
Jun 05, 2015: Corbus Pharmaceuticals Expands Clinical Development of Resunab With a Phase 2 Trial for the Treatment of Rare Disease Dermatomyositis 61
May 13, 2015: Neovacs granted 1.8 million euros in research tax credit 62
Aug 08, 2014: Idera Pharmaceuticals and The Myositis Association Join Forces to Advance the Clinical Development of a Novel TLR Antagonist, IMO-8400, for the Treatment of Myositis 62
Mar 13, 2014: Idera Pharmaceuticals Announces Expansion of Pipeline into Two Orphan Autoimmune Diseases 63
Appendix 64
Methodology 64
Coverage 64
Secondary Research 64
Primary Research 64
Expert Panel Validation 64
Contact Us 64
Disclaimer 65
List of Tables
Number of Products under Development for Dermatomyositis, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Clinical Stage Development, H2 2016 9
Comparative Analysis by Early Stage Development, H2 2016 10
Products under Development by Companies, H2 2016 11
Dermatomyositis - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 12
Dermatomyositis - Pipeline by Hope Pharmaceuticals Inc, H2 2016 13
Dermatomyositis - Pipeline by Idera Pharmaceuticals Inc, H2 2016 14
Dermatomyositis - Pipeline by MedImmune LLC, H2 2016 15
Dermatomyositis - Pipeline by Neovacs SA, H2 2016 16
Dermatomyositis - Pipeline by Novartis AG, H2 2016 17
Assessment by Monotherapy Products, H2 2016 18
Number of Products by Stage and Target, H2 2016 20
Number of Products by Stage and Mechanism of Action, H2 2016 22
Number of Products by Stage and Route of Administration, H2 2016 24
Number of Products by Stage and Molecule Type, H2 2016 26
Dermatomyositis - Dormant Projects, H2 2016 56
List of Figures
Number of Products under Development for Dermatomyositis, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Clinical Stage Development, H2 2016 9
Assessment by Monotherapy Products, H2 2016 18
Number of Products by Targets, H2 2016 19
Number of Products by Stage and Targets, H2 2016 19
Number of Products by Mechanism of Actions, H2 2016 21
Number of Products by Stage and Mechanism of Actions, H2 2016 21
Number of Products by Routes of Administration, H2 2016 23
Number of Products by Stage and Routes of Administration, H2 2016 23
Number of Products by Molecule Types, H2 2016 25
Number of Products by Stage and Molecule Types, H2 2016 25
